Authored By: Sarah
11 Jul 2024

 Red biotechnology Market Size to grow by USD 174.56 billion between 2024-2028

According to a research report “ Red biotechnology Market” by Product (Monoclonal antibodies, Gene therapy, Polyclonal antibodies, Cell-based immunotherapy products, Others) End-user (Pharmaceutical and biotechnology companies, CMOs and CROs, Academic research institutes) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 174.56 billion, at a CAGR of  6.23% during the forecast period. In the dynamic red biotechnology market, genomic research is revolutionizing the industry with its disruptive impact. Red biotechnology, which focuses on medical applications and healthcare, has experienced significant growth due to the increasing importance of genetics. The decoding of the human genome marked a pivotal moment in scientific history, leading to relentless advancements in genomics. These developments have fueled innovation in personalized medicine, diagnostics, and therapeutic interventions. Companies in the red biotechnology sector are harnessing genomic data to create customized therapies, enhancing the precision and efficacy of medical treatments.

Browse market data tables, figures, and in-depth TOC on “Red biotechnology Market” by Product (Monoclonal antibodies, Gene therapy, Polyclonal antibodies, Cell-based immunotherapy products, Others) End-user (Pharmaceutical and biotechnology companies, CMOs and CROs, Academic research institutes) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Product, the Monoclonal antibodies segment is projected to dominate the market size in 2024

Red biotechnology refers to the application of advanced biological techniques, including genetic engineering and recombinant DNA technology, for the production of pharmaceutical products. Pharmaceutical companies are at the forefront of utilizing red biotechnology to develop novel medications for diagnosis, treatment, and prevention of various illnesses. Key tools and methods in red biotechnology include cell culture, monoclonal antibody production, and gene therapy. This market segment is pivotal in addressing unmet medical needs through the creation of innovative therapies, such as vaccines, antibodies, and gene treatments. Pharmaceutical firms are leading the charge in red biotechnology research and development, leveraging these techniques to bring groundbreaking treatments to market.

By End-user, Pharmaceutical and biotechnology companies  segment is expected to hold the largest market size for the year 2024

Monoclonal antibodies hold a significant position in the red biotechnology market, accounting for a substantial market share in the red biotech product arena. The segment has witnessed remarkable growth in recent years, driven by factors such as the rise in chronic diseases, technological advancements, and the burgeoning demand for personalized medicine. Monoclonal antibodies offer a unique value proposition in therapeutic and diagnostic applications due to their ability to provide targeted therapy. This makes them an essential component of the medical and pharmaceutical applications that are the core focus of red biotechnology. The ongoing research and development (R&D) in monoclonal antibodies continue to yield significant breakthroughs, further solidifying their role in the red biotech industry.

North America is forecasted to hold the largest market size by region in 2024

The North American red biotechnology market is a significant and dynamic segment of the global industry, characterized by groundbreaking research and commercialization of medicinal products. With a robust presence of leading biotech companies and renowned academic institutions, North America plays a pivotal role in red biotechnology innovation. Notable red biotech businesses, such as Amgen, a distinguished biopharmaceutical company recognized for its advancements in therapeutic proteins and biologics, are headquartered in the United States, contributing substantially to the North American market's growth.

The Red biotechnology Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Bruker Corp.
  • CRISPR Therapeutics AG
  • Editas Medicine Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck KGaA
  • Mesoblast Ltd.
  • Moderna Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • STEMCELL Technologies Inc.
  • Teva Pharmaceutical Industries Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Red Biotechnology Market encompasses medical devices, diagnostic instruments, medicinal medications, and healthcare solutions derived from medical biotechnology. This sector is a significant contributor to the Biotechnology industry, driving medical innovations through the use of modern technology in manufacturing and development. Genetic factors play a crucial role in Red Biotechnology, leading to advancements in genetic engineering, stem cells, personalized medicine, and gene-based therapies. Key areas of focus include the production of biopharmaceuticals such as vaccines, new drugs, and therapeutic technologies. These advancements are revolutionizing the treatment of rare diseases and cancer through gene therapy. Diagnostic tools, a critical component of Red Biotechnology, are enabling early detection and precise diagnosis, leading to improved patient outcomes. The sector's continuous growth is fueled by the development of cutting-edge technologies and the increasing demand for effective healthcare solutions.

Market Research Overview

The red biotechnology market encompasses various applications of biotechnology in healthcare, focusing on the development of medical innovations for knee joints, kidney diseases, and other health conditions. This sector includes regenerative medicine, bioprinting, and stem cell therapy, which aim to regenerate damaged tissues and organs. Modern technology, such as CRISPR gene-editing, personalized precision medicine, and genetic engineering methods, play a significant role in this field. Subject-related expert advice is crucial in addressing disabilities, genetic susceptibilities, and inherited illnesses like cystic fibrosis and sickle cell anemia. Gene editing and personalized healthcare are paving the way for tailored medicine, including gene treatments for chronic diseases, monoclonal antibodies, and new drugs. The aging population and chronic illnesses require healthcare solutions, with recombinant DNA technologies, gene-based therapies, and biopharmaceuticals leading the charge. Cancer therapies, such as CAR-T cell therapy, and vaccinations for rare diseases are essential advancements in red biotechnology. The biotechnology industry continues to grow, offering diagnostic instruments, medicinal medications, manufacturing, and development of medical devices to cater to the needs of the healthcare sector.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio